Screener
UroGen Pharma URGN Total Assets
Total Assets at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept us-gaap:Assets.
The source filing: UroGen Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 8:05 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025794
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Finance lease right-of-use assets | 4,818 | 5,376 |
| Operating lease right-of-use assets | 2,810 | 3,080 |
| Other non-current assets | 8,761 | 5,161 |
| Total assets | $252,590 | $200,455 |
| Liabilities and Shareholders' Deficit | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $39,945 | $27,717 |
| Employee related accrued expenses | 12,253 | 13,516 |
Item 1. Financial Statements.
FAQ
- What is UroGen Pharma's total assets?
- UroGen Pharma (URGN) reported total assets of $252.59M in Q2 2026.
- How has UroGen Pharma's total assets changed year-over-year?
- UroGen Pharma's total assets increased by 21.0% year-over-year, from $208.72M to $252.59M.
- What is the long-term trend for UroGen Pharma's total assets?
- Over 5 years (2020 to 2025), UroGen Pharma's total assets has grown at a 10.4% compound annual growth rate (CAGR), from $122.01M to $200.46M.
- What does total assets mean?
- The sum of everything the company owns — current assets, property, investments, goodwill, intangibles, and all other assets.
Ask your AI about UroGen Pharma's total assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude